FDA Sets Regulatory Review Period for DUTASTERIDE Patent Extension

Summary

The Food and Drug Administration (FDA) has set a regulatory review period for the patent extension of DUTASTERIDE, a human drug product, following a submission to the Director of Patents and Trademarks, Department of Commerce. This determination is made in accordance with the law and is published as a required notice.